The trial, which is being conducted in partnership with the National Institutes of Health, will study the LY-CoV555 antibody’s effectiveness in preventing COVID-19 contraction among residents and staff at long-term care facilities. It will enroll up to 2,400 residents and staff who live or work at facilities where someone has recently been diagnosed with COVID-19.
The researchers will evaluate whether a single dose of Eli Lilly’s experimental antibody drug decreases the infection rate over four weeks and COVID-19 complications over eight weeks.
“COVID-19 has had a devastating impact on nursing home residents,” Daniel Skovronsky, MD, PhD, Eli Lilly’s chief scientific officer, said in a news release. “We’re working as fast as we can to create medicines that might stop the spread of the virus to these vulnerable individuals. While it’s not easy to conduct clinical trials in this setting, we’re taking on the challenge in an effort to help those who need us the most.”
More articles on pharmacy:
Moderna’s coronavirus vaccine research alleged target of Chinese hackers
Operation Warp Speed: a timeline so far
25% of diabetes patients rationing treatments amid pandemic, survey finds
Moderna’s coronavirus vaccine research alleged target of Chinese hackers
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.